Voyager Therapeutics (VYGR) Other Non Operating Income (2016 - 2026)
Voyager Therapeutics (VYGR) posted Other Non Operating Income of $435000.0 for Q1 2026, up 412.95% sequentially from -$139000.0 in Q4 2025, and up 4.07% YoY from $418000.0 in Q1 2025.
Voyager Therapeutics (VYGR) Other Non Operating Income (2016 - 2026) Analysis & Trends
Voyager Therapeutics has reported Other Non Operating Income for 11 years, with the latest figure at $435000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 4.07% year-over-year to $435000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 7.98% YoY) and the FY2025 annual result came in at $1.1 million, up 77.81% from the prior year.
- Other Non Operating Income advanced to $435000.0 in Q1 2026 per VYGR's latest filing, from -$139000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $2.6 million in Q3 2022 and troughed at -$139000.0 in Q4 2025.
- A 5-year average of $374769.2 and a median of $200000.0 in 2024 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income jumped 2454.46% in 2022, then plunged 134.58% in 2025.
- Over 5 years, Other Non Operating Income stood at -$23000.0 in 2022, then jumped by 234.78% to $31000.0 in 2023, then jumped by 1196.77% to $402000.0 in 2024, then slumped by 134.58% to -$139000.0 in 2025, then surged by 412.95% to $435000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $435000.0, -$139000.0, and $400000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Voyager Therapeutics | 205.86 Mn | 89.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 411,000.00 |
| Mar 31, 2026 | 435,000.00 |
| Dec 31, 2025 | -139,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 427,000.00 |
| Mar 31, 2025 | 418,000.00 |
| Dec 31, 2024 | 402,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Jun 30, 2023 | 3,000.00 |
| Dec 31, 2022 | -23,000.00 |
| Sep 30, 2022 | 2.64 Mn |
| Jun 30, 2022 | 61,000.00 |
| Dec 31, 2021 | 650,000.00 |
| Sep 30, 2021 | -112,000.00 |
| Jun 30, 2021 | -1.58 Mn |
| Mar 31, 2021 | 3.92 Mn |
| Dec 31, 2020 | 7.72 Mn |
| Sep 30, 2020 | 830,000.00 |